SAN DIEGO and SUZHOU, China – February 17, 2026 – Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a firm revolutionizing the discovery and advancement of innovative antibody-based treatments, revealed today that Mickael Chane-Du, its Chief Strategy Officer, will take part in individual investor meetings and a fireside chat at two upcoming events: the Oppenheimer 36th Annual Healthcare Life Sciences Conference (hosted virtually on February 25, 2026) and the Leerink Global Healthcare Conference (held in Miami, Florida from March 8–11, 2026).
Oppenheimer 36th Annual Healthcare Life Sciences Conference (Virtual)
- Format: Fireside chat
- Date/Time: Wednesday, February 25, 2026 at 4:00 PM (Eastern Time)
- Webcast:
Leerink Global Healthcare Conference
- Format: Fireside chat
- Date/Time: Monday, March 9, 2026 at 4:20 PM (Eastern Time)
- Webcast:
If you wish to meet with Adagene’s management team during these conferences, please connect with your respective conference representative.
A webcast of the presentations will be available in the section of the Company’s website at for a minimum of 30 days.
Recently, the Company presented at the Guggenheim Emerging Outlook: Biotech Summit 2026, which took place February 11–12, 2026 in New York City. A webcast of this presentation can be accessed on the Company’s website and directly via the following link: .
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company dedicated to transforming the discovery and development of cutting-edge antibody-based cancer immunotherapies. Adagene integrates computational biology and artificial intelligence to engineer innovative antibodies that address unmet medical needs across the globe. The company has established strategic partnerships with esteemed international collaborators that leverage its SAFEbody precision masking technology in multiple forward-thinking scientific approaches.
Powered by its proprietary Dynamic Precision Library (DPL) platform—comprising NEObody™, SAFEbody, and POWERbody™ technologies—Adagene’s highly distinct pipeline features novel immunotherapy initiatives. The company’s SAFEbody technology is designed to tackle safety and tolerability challenges associated with many antibody therapeutics by using precision masking to shield the binding domain of the biologic treatment. Activation within the tumor microenvironment enables tumor-specific targeting of antibodies while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s flagship clinical program, muzastotug (ADG126), is a masked anti-CTLA-4 SAFEbody with FDA Fast Track designation that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) within the tumor microenvironment. Muzastotug is currently undergoing Phase 1b/2 and Phase 2 clinical trials in combination with anti-PD-1 therapy, with a specific focus on microsatellite stable (MSS) metastatic colorectal cancer (CRC). Supported by ongoing clinical research, the SAFEbody platform can be applied to a broad range of antibody-based therapeutic modalities, including Fc-enhanced antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers.
For more information, please visit: .
Follow Adagene on , and X.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Investor Contacts:
Raymond Tam
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
